Hubei Biocause Pharmaceutical Co., Ltd. announced on 24 April 2023 the final profit distribution proposal for 2022 as Cash dividend/10 shares (tax included): CNY 1.10000000.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.73 CNY | +0.58% |
|
-1.70% | -39.08% |
Jul. 09 | Biocause Pharmaceutical's Insurance Arm Logs 25 Billion Yuan in Annual Insurance Premium | MT |
Jun. 17 | Biocause Pharma Plans Buyback of Up to 100 Million Yuan Shares | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-39.08% | 1.18B | |
+9.36% | 77.41B | |
+12.35% | 52.64B | |
+10.95% | 52.19B | |
+26.37% | 48.49B | |
+18.86% | 44.26B | |
+23.27% | 39.65B | |
+16.44% | 33.1B | |
+43.61% | 29.62B | |
-8.64% | 27.43B |
- Stock Market
- Equities
- 000627 Stock
- News Hubei Biocause Pharmaceutical Co., Ltd.
- Hubei Biocause Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2022